Wockhardt is locked in lower circuit of 10% at Rs 575, extending its past six days fall, after the US Food and Drug Administration (USFDA) on July 18, issued a warning letter to the company for its manufacturing facility in Maharashtra.
The pharmaceutical stock, currently trading at its lowest level since April 2012, has underperformed falling 41% in past seven trading days from Rs 975 on July 17, as compared to 0.57% fall in S&P BSE Sensex.
A combined 1.38 million shares changed hands on the counter and there are pending sell orders for 110,123 shares on BSE and NSE at 1157 hours.
In its letter dated July 18, addressed to Dr. Habil Khorakiwala, founder of the company, the FDA said it might freeze approvals for any new launches Wockhardt was planning in America until the company addressed its concerns about the Waluj plant.
FDA also recommended Wockhardt hire independent auditors to review its operations at Waluj and asked the company to detail its plan for an upgrade.
According to Wockhardt, the US FDA import alert will cause an annual loss of $100 million (Rs 600 crore).
The pharmaceutical stock, currently trading at its lowest level since April 2012, has underperformed falling 41% in past seven trading days from Rs 975 on July 17, as compared to 0.57% fall in S&P BSE Sensex.
A combined 1.38 million shares changed hands on the counter and there are pending sell orders for 110,123 shares on BSE and NSE at 1157 hours.
In its letter dated July 18, addressed to Dr. Habil Khorakiwala, founder of the company, the FDA said it might freeze approvals for any new launches Wockhardt was planning in America until the company addressed its concerns about the Waluj plant.
FDA also recommended Wockhardt hire independent auditors to review its operations at Waluj and asked the company to detail its plan for an upgrade.
According to Wockhardt, the US FDA import alert will cause an annual loss of $100 million (Rs 600 crore).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%